Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of Fluorescence Spectroscopy
Lakowicz, J. R. (1999) · Springer eBooks · doi:10.1007/978-1-4757-3061-6 · Cited by 26,947 · cited 1×
“Self-quenching, which results in a slight decrease in MCF with increasing concentration of fluorophore, occurs with the ‘crowding’ of fluorophores in localized regions in the proximity of 50–100 Å [28]; an indication of the molecular crowding and high density of biotin-PE at the surface of the particles.”
BackgroundBiodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361 · cited 1×
“This unique combination of properties—coupled with flexibility over fabrication— has led to interest in modifying the PLGA surface for specific attachment to cells or organs in the body [6,8–12], which may be of interest in both drug delivery and tissue engineering applications.”
BackgroundBiodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617 · cited 2×
“molecules under physiologic conditions while degrading to nontoxic, low-molecular-weight products that are readily eliminated [4,5].”
BackgroundJain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214 · cited 1×
“(4) Control over PLGA manufacturing into nanoscale particles (o500 nm) for potential evasion of the immune phagocytic system or fabrication into microparticles on the length scale of cells for targeted delivery of drugs or as antigenpresenting systems [6,7].”
BackgroundPreparation and characterization of poly(l-lactic acid) foams
Mikos, A. G., Thorsen, A. J., Czerwonka, L. A., Bao, Y., Langer, R., Winslow, D. N., & Vacanti, J. P. (1994) · Polymer · doi:10.1016/0032-3861(94)90953-9 · Cited by 1,187
Polymers for the sustained release of proteins and other macromolecules
LANGER, R., & FOLKMAN, J. (1976) · Nature · doi:10.1038/263797a0 · Cited by 1,182 · cited 1×
“This importance derives from: (1) Physiologic compatibility of PLGA and its homopolymers PGA and PLA, all of which have been established as safe in humans after 30 years in various biomedical applications including drug delivery systems [1–3].”
BackgroundMu, L., & Feng, S. S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00320-6 · Cited by 725 · cited 1×
“Others have found similar effects on the encapsulation efficiency and particle yields with the addition of pegylated Vitamin-E or the lipid DPPC to a PLGA emulsion [30,31].”
BackgroundPrinciples of fluorescence spectroscopy
Ricchelli, F. (1989) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(89)80070-3 · Cited by 621
Biodegradable Nanoparticles for Targeted Drug Delivery in Treatment of Inflammatory Bowel Disease
Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Maincent, P., Kawashima, Y., & Lehr, C.-M. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29290-9 · Cited by 403 · cited 1×
“This unique combination of properties—coupled with flexibility over fabrication— has led to interest in modifying the PLGA surface for specific attachment to cells or organs in the body [6,8–12], which may be of interest in both drug delivery and tissue engineering applications.”
BackgroundCroll, T. I., O'Connor, A. J., Stevens, G. W., & Cooper-White, J. J. (2004) · Biomacromolecules · doi:10.1021/bm0343040 · Cited by 402 · cited 1×
“Another approach involves the blending or adsorption of functional polymers such as polylysine [15,16] or poly(ethylene-alt-maleic acid) (PEMA) [17] or Polyethylene glycol (PEG) [18] into PLGA and forming particles and matrices from these blends [16,17,19–21].”
Background
Cited by
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Polylactic acid: Synthesis and biomedical applications
Singhvi, M. S., Zinjarde, S. S., & Gokhale, D. V. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14290 · Cited by 883
Liu, Y., Miyoshi, H., & Nakamura, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22709 · Cited by 620
Various methods of gold nanoparticles (GNPs) conjugation to antibodies
Jazayeri, M. H., Amani, H., Pourfatollah, A. A., Pazoki-Toroudi, H., & Sedighimoghaddam, B. (2016) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2016.04.002 · Cited by 528
The uptake and intracellular fate of PLGA nanoparticles in epithelial cells
Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J., & Saltzman, W. M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.057 · Cited by 412
“Moreover, knowledge of the intracellular fate of unmodified PLGA NPs can serve as a baseline for design of surface-modified NPs intended for improved, targeted delivery [28,29].”
Self-citationPLA Nano‐ and Microparticles for Drug Delivery: An Overview of the Methods of Preparation
Lassalle, V., & Ferreira, M. L. (2007) · Macromolecular Bioscience · doi:10.1002/mabi.200700022 · Cited by 340
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
Park, J., Fong, P. M., Lu, J., Russell, K. S., Booth, C. J., Saltzman, W. M., & Fahmy, T. M. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.02.002 · Cited by 339
Self-citationMohamed, F., & van der Walle, C. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21082 · Cited by 299
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
Demento, S. L., Eisenbarth, S. C., Foellmer, H. G., Platt, C., Caplan, M. J., Mark Saltzman, W., Mellman, I., Ledizet, M., Fikrig, E., Flavell, R. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.034 · Cited by 290
Self-citationPoly(Lactic Acid)-Based Biomaterials: Synthesis, Modification and Applications
Xiao, L., Wang, B., Yang, G., & Gauthier, M. (2012) · Biomedical Science, Engineering and Technology · doi:10.5772/23927 · Cited by 277
Naderi, H., Matin, M. M., & Bahrami, A. R. (2011) · Journal of Biomaterials Applications · doi:10.1177/0885328211408946 · Cited by 274
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou, J., Patel, T. R., Sirianni, R. W., Strohbehn, G., Zheng, M.-Q., Duong, N., Schafbauer, T., Huttner, A. J., Huang, Y., Carson, R. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304504110 · Cited by 271
Cu, Y., & Saltzman, W. M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8001254 · Cited by 267
Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells
Eggermont, L. J., Paulis, L. E., Tel, J., & Figdor, C. G. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.06.007 · Cited by 217
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors
Zhou, J., Patel, T. R., Fu, M., Bertram, J. P., & Saltzman, W. M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.061 · Cited by 176
The impact of nanoparticle ligand density on dendritic-cell targeted vaccines
Bandyopadhyay, A., Fine, R. L., Demento, S., Bockenstedt, L. K., & Fahmy, T. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.054 · Cited by 141
Self-citationFeng, G., Jiang, Q., Xia, M., Lu, Y., Qiu, W., Zhao, D., Lu, L., Peng, G., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061135 · Cited by 108
RetractedTargeted binding of PLA microparticles with lipid-PEG-tethered ligands
Duncanson, W. J., Figa, M. A., Hallock, K., Zalipsky, S., Hamilton, J. A., & Wong, J. Y. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.044 · Cited by 75
Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment
Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61
Metadata
- Authors
- Fahmy, T. M., Samstein, R. M., Harness, C. C., & Mark Saltzman, W.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 26
- Issue
- 28
- Pages
- 5727-5736
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2027237928
- Cited by
- 194
- References
- 31
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.